Evidence map›Paper›PMID 31099181›Full record

ReviewStem cells translational medicine2019

Concise Review: Stem Cell Therapy for Stroke Patients: Are We There Yet?

Cesario V Borlongan

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Stem cells translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 2 pooled it
12.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 2 syntheses or guidelines pooled it, 135 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Brain repair mechanisms after cell therapy for stroke.Brain : a journal of neurology · 2024
    Review
  16. An update on stem cell therapy for stroke patients: Where are we now?Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2024
    Review
  17. Review
  18. Article
  19. Article
  20. Review

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Cesario V BorlonganCenter of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair, University of South Florida Morsani College of Medicine, Tampa, Florida, USA.ORCID 0000-0002-2966-9782
University of South Florida · US

Funding

MR Analysis of Pre-Conditioned Human Mesenchymal Stem Cells for Stroke TherapyR01NS102395 · NINDS · FLORIDA STATE UNIVERSITY · PI GRANT, SAMUEL COLLES · 2017 to 2021
$1.7M
Re-Establishing Vascular Integrity in ALS via Endothelial Cell TransplantR01NS090962 · NINDS · UNIVERSITY OF SOUTH FLORIDA · PI BORLONGAN, CESARIO V, GARBUZOVA-DAVIS, SVITLANA NICOLAI · 2015 to 2019
$1.6M
Optimizing Approaches to Endovascular Therapy of Acute Ischemic StrokeR21NS109575 · NINDS · UNIVERSITY OF SOUTH FLORIDA · PI MOKIN, MAXIM · 2019 to 2019
$420k
NINDS NIH HHS R01 NS090962NINDS NIH HHS R01 NS102395NINDS NIH HHS R21 NS109575
6 · The paper itself

Abstract

Four decades of preclinical research demonstrating survival, functional integration, and behavioral effects of transplanted stem cells in experimental stroke models have provided ample scientific basis for initiating limited clinical trials of stem cell therapy in stroke patients. Although safety of the grafted cells has been overwhelmingly documented, efficacy has not been forthcoming. Two recently concluded stroke clinical trials on mesenchymal stem cells (MSCs) highlight the importance of strict adherence to the basic science findings of optimal transplant regimen of cell dose, timing, and route of delivery in enhancing the functional outcomes of cell therapy. Echoing the Stem Cell Therapeutics as an Emerging Paradigm for Stroke and Stroke Treatment Academic Industry Roundtable call for an NIH-guided collaborative consortium of multiple laboratories in testing the safety and efficacy of stem cells and their derivatives, not just as stand-alone but preferably in combination with approved thrombolytic or thrombectomy, may further increase the likelihood of successful fruition of translating stem cell therapy for stroke clinical application. The laboratory and clinical experience with MSC therapy for stroke may guide the future translational research on stem cell-based regenerative medicine in neurological disorders. Stem Cells Translational Medicine 2019;8:983&988.

Indexed as

Mesenchymal Stem Cell TransplantationCell- and Tissue-Based TherapyClinical Trials as TopicHumansMesenchymal Stem CellsRegenerative MedicineStrokeTranslational Research, BiomedicalBasic scienceCerebral ischemiaClinicalRegenerative medicineStem cell transplantationTranslation

Identifiers

PMID31099181
PMCPMC6708064
OpenAlexW2946508262

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.